MX2022015044A - Formulaciones y metodos para tratar el sindrome de dificultad respiratoria aguda, asma o rinitis alergica. - Google Patents

Formulaciones y metodos para tratar el sindrome de dificultad respiratoria aguda, asma o rinitis alergica.

Info

Publication number
MX2022015044A
MX2022015044A MX2022015044A MX2022015044A MX2022015044A MX 2022015044 A MX2022015044 A MX 2022015044A MX 2022015044 A MX2022015044 A MX 2022015044A MX 2022015044 A MX2022015044 A MX 2022015044A MX 2022015044 A MX2022015044 A MX 2022015044A
Authority
MX
Mexico
Prior art keywords
asthma
allergic rhinitis
formulations
methods
respiratory distress
Prior art date
Application number
MX2022015044A
Other languages
English (en)
Spanish (es)
Inventor
Sadasivan Vidyasagar
Astrid Grosche
Xiaodong Xu
Damiano Angoli
Stephen J Gatto
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of MX2022015044A publication Critical patent/MX2022015044A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022015044A 2020-05-29 2021-05-28 Formulaciones y metodos para tratar el sindrome de dificultad respiratoria aguda, asma o rinitis alergica. MX2022015044A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063032185P 2020-05-29 2020-05-29
US202063080470P 2020-09-18 2020-09-18
US202063088813P 2020-10-07 2020-10-07
US202163136404P 2021-01-12 2021-01-12
PCT/US2021/034807 WO2021243183A1 (en) 2020-05-29 2021-05-28 Formulations and methods for treating acute respiratory distress syndrome, asthma, or allergic rhinitis

Publications (1)

Publication Number Publication Date
MX2022015044A true MX2022015044A (es) 2023-01-04

Family

ID=78722883

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015044A MX2022015044A (es) 2020-05-29 2021-05-28 Formulaciones y metodos para tratar el sindrome de dificultad respiratoria aguda, asma o rinitis alergica.

Country Status (10)

Country Link
US (1) US20230201151A1 (https=)
EP (1) EP4157218A4 (https=)
JP (1) JP2023531872A (https=)
KR (1) KR20230018474A (https=)
CN (1) CN115697301A (https=)
AU (1) AU2021280328A1 (https=)
BR (1) BR112022024033A2 (https=)
CA (1) CA3177780A1 (https=)
MX (1) MX2022015044A (https=)
WO (1) WO2021243183A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116036277B (zh) * 2022-07-19 2023-10-31 广州国家实验室 氯离子在预防、治疗冠状病毒所致疾病中的应用
US11878073B1 (en) 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6686340B2 (en) * 2001-06-19 2004-02-03 Matthias Rath Composition and method for prevention and treatment of health conditions caused by constriction of smooth muscle cells
CN104207146A (zh) * 2014-07-26 2014-12-17 胡安然 呼吸系统疾病全营养配方食品
EP3691628A1 (en) * 2017-10-02 2020-08-12 University of Florida Research Foundation, Incorporated Materials and methods for inhibiting tumor growth
WO2019070759A1 (en) * 2017-10-02 2019-04-11 University Of Florida Research Foundation Incorporated AMINO ACID COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS
CA3116015A1 (en) * 2018-10-30 2020-05-07 University Of Florida Research Foundation, Incorporated Amino acid compositions and methods for treating cystic fibrosis

Also Published As

Publication number Publication date
KR20230018474A (ko) 2023-02-07
BR112022024033A2 (pt) 2022-12-20
US20230201151A1 (en) 2023-06-29
WO2021243183A8 (en) 2022-01-13
WO2021243183A1 (en) 2021-12-02
AU2021280328A1 (en) 2022-11-17
CN115697301A (zh) 2023-02-03
EP4157218A4 (en) 2024-06-26
JP2023531872A (ja) 2023-07-26
EP4157218A1 (en) 2023-04-05
CA3177780A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
EP4684836A3 (en) Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
CA2474479A1 (en) Composition for inhalation
MX2025004666A (es) Uso de oxido nitrico inhalado para el tratamiento de la hipertension pulmonar asociada con enfermedades pulmonares
MY208001A (en) A subunit vaccine for treatment or prevention of a respiratory tract infection
MX2022012359A (es) Formulacion.
JP2017532343A5 (https=)
MX2022015044A (es) Formulaciones y metodos para tratar el sindrome de dificultad respiratoria aguda, asma o rinitis alergica.
NO20063047L (no) Vandige ciclesonidsuspensjoner for forstoving
MX2025003477A (es) Uso de reboxetina para el tratamiento de narcolepsia
MX2023006205A (es) Tratamiento y diagnostico fotodinamico.
WO2018094023A3 (en) Cyclic dipeptides and wound healing
WO2021212013A3 (en) Bioactive peptides and methods of use thereof
WO2015106215A3 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MY197917A (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
JOP20240043A1 (ar) مشتقات s-ألانينات تحمل بدائل
WO2023122280A3 (en) Compositions and methods for treating skin defects
MX2020001084A (es) Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial.
MX2022012001A (es) Tratamiento preventivo de la migra?a.
WO2019099860A3 (en) Wound treatment containing collagen and a gelatin-reducing agent, and method for promoting wound healing
EP3295932A3 (en) Stable odf composition containing hardly soluble therapeutic agent
PT4199922T (pt) Ácido (1r,3s)-3-((5-ciano-4-feniltiazol-2- il)carbamoil)ciclopentano-1-carboxílico para uso no tratamento de doenças das vias respiratórias
EA201991530A1 (ru) Композиции и способы лечения биопленок
MX2019001854A (es) Formulacion farmaceutica estable que comprende una composicion de tensioactivo pulmonar reconstituido.
WO2023240193A3 (en) Fitusiran for the treatment of hemophilia a and b in pediatric patients
JOP20210315B1 (ar) إستر لـ -حمض أسيتيك أيزو بروبيل لعلاج السعال المزمن